-
1
-
-
4544278198
-
Glucose transporter and Na+/glucose cotransporter as molecular targets of anti-diabetic drugs
-
1:CAS:528:DC%2BD2cXns1Sku7o%3D
-
Asano, T., T. Ogihara, H. Katagiri, H. Sakoda, H. Ono, M. Fujishiro, M. Anai, H. Kurihara, and Y. Uchijima. 2004. Glucose transporter and Na+/glucose cotransporter as molecular targets of anti-diabetic drugs. Current Medicinal Chemistry 11: 2717-2724.
-
(2004)
Current Medicinal Chemistry
, vol.11
, pp. 2717-2724
-
-
Asano, T.1
Ogihara, T.2
Katagiri, H.3
Sakoda, H.4
Ono, H.5
Fujishiro, M.6
Anai, M.7
Kurihara, H.8
Uchijima, Y.9
-
2
-
-
77953857048
-
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, double-blind, placebo-controlled trial
-
1:CAS:528:DC%2BC3cXotVagtro%3D
-
Bailey, C.J., J.L. Gross, A. Pieters, A. Bastien, and J.F. List. 2010. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, double-blind, placebo-controlled trial. Lancet 375: 2223-2233.
-
(2010)
Lancet
, vol.375
, pp. 2223-2233
-
-
Bailey, C.J.1
Gross, J.L.2
Pieters, A.3
Bastien, A.4
List, J.F.5
-
3
-
-
35448978003
-
Meglitinide analogues for type 2 diabetes mellitus
-
Black, C., P. Donnelly, L. Mcintyre, P.L. Royle, J.P. Shepherd, and S. Thomas. 2007. Meglitinide analogues for type 2 diabetes mellitus. The Cochrane Database of Systematic Reviews 2: CD4654.
-
(2007)
The Cochrane Database of Systematic Reviews
, vol.2
, pp. 4654
-
-
Black, C.1
Donnelly, P.2
McIntyre, L.3
Royle, P.L.4
Shepherd, J.P.5
Thomas, S.6
-
4
-
-
84880543926
-
Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: A randomized trial
-
Bode, B., K. Stenlöf, D. Sullivan, A. Fung, and K. Usiskin. 1995. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: A randomized trial. Hospital Practice 41: 72-84.
-
(1995)
Hospital Practice
, vol.41
, pp. 72-84
-
-
Bode, B.1
Stenlöf, K.2
Sullivan, D.3
Fung, A.4
Usiskin, K.5
-
5
-
-
84858020943
-
Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin
-
1:CAS:528:DC%2BC38Xkt1yms78%3D
-
Bolinder, J., O. Ljunggren, J. Kullberg, L. Johansson, J. Wildding, A.M. Langkilde, J. Sugg, and S. Parikh. 2012. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. The Journal of Clinical Endoclinology & Metabolism 97: 1020-1031.
-
(2012)
The Journal of Clinical Endoclinology & Metabolism
, vol.97
, pp. 1020-1031
-
-
Bolinder, J.1
Ljunggren, O.2
Kullberg, J.3
Johansson, L.4
Wildding, J.5
Langkilde, A.M.6
Sugg, J.7
Parikh, S.8
-
6
-
-
47149095990
-
Pancreatic alphacell dysfunction in diabetes
-
1:CAS:528:DC%2BD1cXnvVGgs7s%3D
-
Burcelin, R., C. Knauf, and P.D. Cani. 2008. Pancreatic alphacell dysfunction in diabetes. Diabetes Metabolism 34: S49-S55.
-
(2008)
Diabetes Metabolism
, vol.34
, pp. 49-S55
-
-
Burcelin, R.1
Knauf, C.2
Cani, P.D.3
-
7
-
-
0032952105
-
Insulin regulation of renal glucose metabolism in humans
-
1:CAS:528:DyaK1MXntlaqug%3D%3D 9886953
-
Cersosimo, E., P. Garlick, and J. Ferretti. 1999. Insulin regulation of renal glucose metabolism in humans. American Journal of Physiology 276: E78-E84.
-
(1999)
American Journal of Physiology
, vol.276
, pp. 78-E84
-
-
Cersosimo, E.1
Garlick, P.2
Ferretti, J.3
-
8
-
-
77954242599
-
SGLT2 inhibition: A novel strategy for diabetes treatment
-
1:CAS:528:DC%2BC3cXmsF2itLc%3D
-
Chao, E.C., and R.R. Henry. 2010. SGLT2 inhibition: A novel strategy for diabetes treatment. Nature Reviews Drug Discovery 9: 551-559.
-
(2010)
Nature Reviews Drug Discovery
, vol.9
, pp. 551-559
-
-
Chao, E.C.1
Henry, R.R.2
-
9
-
-
73249141243
-
11β-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation
-
Copper, M.S., and P.M. Stewart. 2009. 11β-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. The Journal of Clinical Endocrinology and Metabolism 94: 4645-4654.
-
(2009)
The Journal of Clinical Endocrinology and Metabolism
, vol.94
, pp. 4645-4654
-
-
Copper, M.S.1
Stewart, P.M.2
-
10
-
-
77956164758
-
American Diabetes Association: 70th scientific sessions: Research on novel therapeutics: Part 1
-
Croasdell, G. 2010. American Diabetes Association: 70th scientific sessions: Research on novel therapeutics: Part 1. The Investigational Dugs Journal 13: 595-597.
-
(2010)
The Investigational Dugs Journal
, vol.13
, pp. 595-597
-
-
Croasdell, G.1
-
11
-
-
0037034257
-
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
-
Diabetes Prevention Program Research Group
-
Diabetes Prevention Program Research Group. 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine 364: 393-403.
-
(2002)
The New England Journal of Medicine
, vol.364
, pp. 393-403
-
-
-
12
-
-
33846006173
-
The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
-
1:CAS:528:DC%2BD28XhtF2gurjM
-
Drucker, D.J., and M.A. Nauck. 2006. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705.
-
(2006)
Lancet
, vol.368
, pp. 1696-1705
-
-
Drucker, D.J.1
Nauck, M.A.2
-
13
-
-
4544233390
-
Glycosylated dihydrochalcones as potent and selective sodium glucose co-transporters 2 (SGLT2) inhibitors
-
1:CAS:528:DC%2BD2cXns1Ohurc%3D
-
Dudash Jr, J., X. Zhang, R.E. Zeck, S.G. Johnson, G.G. Cox, B.R. Conway, P.J. Rybczynski, and K.T. Demarest. 2004. Glycosylated dihydrochalcones as potent and selective sodium glucose co-transporters 2 (SGLT2) inhibitors. Bioorganic & Medicinal Chemistry Letters 14: 5121-5125.
-
(2004)
Bioorganic & Medicinal Chemistry Letters
, vol.14
, pp. 5121-5125
-
-
Dudash, Jr.J.1
Zhang, X.2
Zeck, R.E.3
Johnson, S.G.4
Cox, G.G.5
Conway, B.R.6
Rybczynski, P.J.7
Demarest, K.T.8
-
14
-
-
63849342369
-
Current strategies for the inhibition of hepatic glucose production in type 2 diabetes
-
1:CAS:528:DC%2BD1MXltFejtbs%3D
-
Edgerton, D.S., K.M. Johnson, and A.D. Cherrington. 2009. Current strategies for the inhibition of hepatic glucose production in type 2 diabetes. Frontiers in Bioscience 14: 1169-1181.
-
(2009)
Frontiers in Bioscience
, vol.14
, pp. 1169-1181
-
-
Edgerton, D.S.1
Johnson, K.M.2
Cherrington, A.D.3
-
15
-
-
12744253796
-
Phlorizin: A review
-
1:CAS:528:DC%2BD2MXhs12gs7c%3D
-
Ehrenkranz, R.R.L., N.G. Lewis, C.R. Kahn, and J. Roth. 2005. Phlorizin: A review. Diabetes Metabolism Research Reviews 21: 31-38.
-
(2005)
Diabetes Metabolism Research Reviews
, vol.21
, pp. 31-38
-
-
Ehrenkranz, R.R.L.1
Lewis, N.G.2
Kahn, C.R.3
Roth, J.4
-
16
-
-
84939917152
-
FDA Briefing Document. NDA 202293. Dapagliflozin Tablets, 5 and 10 Mg. Sponsor: Bristol-Myers Squibb
-
FDA
-
FDA. 2011. FDA briefing document. NDA 202293. Dapagliflozin tablets, 5 and 10 mg. Sponsor: Bristol-Myers Squibb. Advisory Committee Meeting.
-
(2011)
Advisory Committee Meeting
-
-
-
17
-
-
84898791440
-
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
-
1:CAS:528:DC%2BC2cXmsFWrtL0%3D
-
Forst, T., R. Guthrie, R. Goldenberg, J. Yee, U. Vijapurkar, G. Meininger, and P. Stein. 2014. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes, Obesity & Metabolism 16: 467-477.
-
(2014)
Diabetes, Obesity & Metabolism
, vol.16
, pp. 467-477
-
-
Forst, T.1
Guthrie, R.2
Goldenberg, R.3
Yee, J.4
Vijapurkar, U.5
Meininger, G.6
Stein, P.7
-
18
-
-
52649083832
-
Remogliflozin etabonate, in a novel category of selective low-affinity/high-capacity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models
-
1:CAS:528:DC%2BD1cXht1amsLfL
-
Fujimori, Y., K. Katsuno, I. Nakashima, Y. Ishikawa-Takemura, H. Fujikura, and M. Isaji. 2008. Remogliflozin etabonate, in a novel category of selective low-affinity/high-capacity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. The Journal of Pharmacology and Experimental Therapeutics 327: 268-276.
-
(2008)
The Journal of Pharmacology and Experimental Therapeutics
, vol.327
, pp. 268-276
-
-
Fujimori, Y.1
Katsuno, K.2
Nakashima, I.3
Ishikawa-Takemura, Y.4
Fujikura, H.5
Isaji, M.6
-
19
-
-
83655184724
-
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitors
-
1:CAS:528:DC%2BC38XhvFOmsb8%3D
-
Grempler, R., L. Thomas, M. Eckhardt, F. Himmelsbach, A. Sauer, D.E. Sharp, R.A. Bakker, M. Mark, T. Klein, and P. Eickelmann. 2012. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitors. Diabetes, Obesity & Metabolism 14: 83-90.
-
(2012)
Diabetes, Obesity & Metabolism
, vol.14
, pp. 83-90
-
-
Grempler, R.1
Thomas, L.2
Eckhardt, M.3
Himmelsbach, F.4
Sauer, A.5
Sharp, D.E.6
Bakker, R.A.7
Mark, M.8
Klein, T.9
Eickelmann, P.10
-
20
-
-
3042661013
-
Effects of hyperglycemia, glucagon, and epinephrine on renal glucose release in the conscious dog
-
1:CAS:528:DC%2BD2cXlt1eltb0%3D
-
Gustavson, S.M., et al. 2004. Effects of hyperglycemia, glucagon, and epinephrine on renal glucose release in the conscious dog. Metabolism 53: 933-941.
-
(2004)
Metabolism
, vol.53
, pp. 933-941
-
-
Gustavson, S.M.1
-
21
-
-
38049083706
-
Compound K enhances insulin secretion with beneficial metabolic effects in db/db mice
-
1:CAS:528:DC%2BD2sXhtlCqtLbN
-
Han, G.C., S.K. Ko, J.H. Sung, and S.H. Chung. 2007. Compound K enhances insulin secretion with beneficial metabolic effects in db/db mice. Journal of Agricultural and Food Chemistry 55: 10641-10648.
-
(2007)
Journal of Agricultural and Food Chemistry
, vol.55
, pp. 10641-10648
-
-
Han, G.C.1
Ko, S.K.2
Sung, J.H.3
Chung, S.H.4
-
22
-
-
48249146624
-
Dapagliflozin: A selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats
-
1:CAS:528:DC%2BD1cXnsF2isL4%3D
-
Han, S., D.L. Hagan, J.R. Taylor, L. Xin, W. Meng, S.A. Biller, J.R. Wetterau, W.N. Washburn, and J.M. Whaley. 2008. Dapagliflozin: A selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57: 1723-1729.
-
(2008)
Diabetes
, vol.57
, pp. 1723-1729
-
-
Han, S.1
Hagan, D.L.2
Taylor, J.R.3
Xin, L.4
Meng, W.5
Biller, S.A.6
Wetterau, J.R.7
Washburn, W.N.8
Whaley, J.M.9
-
23
-
-
0027948971
-
Molecular physiology of sodium-glucose cotransporters
-
1:CAS:528:DyaK2MXitFGnsLs%3D 7938229
-
Hediger, M.A., and D.B. Rhoads. 1994. Molecular physiology of sodium-glucose cotransporters. Physiological Reviews 74: 993-1026.
-
(1994)
Physiological Reviews
, vol.74
, pp. 993-1026
-
-
Hediger, M.A.1
Rhoads, D.B.2
-
24
-
-
0023567264
-
Expression cloning and cDNA sequencing of the Na(+)/glucose co-transporter
-
1:CAS:528:DyaL1cXhsVCnsbg%3D
-
Hediger, M.A., M.J. Coady, T.S. Ikeda, and E.M. Wright. 1987. Expression cloning and cDNA sequencing of the Na(+)/glucose co-transporter. Nature 330: 379-381.
-
(1987)
Nature
, vol.330
, pp. 379-381
-
-
Hediger, M.A.1
Coady, M.J.2
Ikeda, T.S.3
Wright, E.M.4
-
25
-
-
0031770812
-
Na(+)-glucose cotransporter inhibitors as antidiabetic agents. III. Synthesis and pharmacological properties of 4-dehydroxyphlorizin derivatives modified at the OH groups of the glucose moiety
-
1:CAS:528:DyaK1cXntVSlt74%3D
-
Hongu, M., N. Funami, Y. Takahashi, K. Saito, K. Arakawa, M. Matsumoto, H. Yamakita, and K. Tsujihara. 1998a. Na(+)-glucose cotransporter inhibitors as antidiabetic agents. III. Synthesis and pharmacological properties of 4-dehydroxyphlorizin derivatives modified at the OH groups of the glucose moiety. Chemical & Pharmaceutical Bulletin (Tokyo) 46: 1545-1555.
-
(1998)
Chemical & Pharmaceutical Bulletin (Tokyo)
, vol.46
, pp. 1545-1555
-
-
Hongu, M.1
Funami, N.2
Takahashi, Y.3
Saito, K.4
Arakawa, K.5
Matsumoto, M.6
Yamakita, H.7
Tsujihara, K.8
-
26
-
-
0031934860
-
Na(+)-glucose cotransporter inhibitors as antidiabetic agents. II. Synthesis and structure-activity relationships of 4-dehydroxyphlorizin derivatives
-
1:CAS:528:DyaK1cXnsFegsw%3D%3D
-
Hongu, M., T. Tanaka, N. Funami, K. Saito, K. Arakawa, M. Matsumoto, and K. Tsujihara. 1998b. Na(+)-glucose cotransporter inhibitors as antidiabetic agents. II. Synthesis and structure-activity relationships of 4-dehydroxyphlorizin derivatives. Chemical & Pharmaceutical Bulletin (Tokyo) 46: 22-33.
-
(1998)
Chemical & Pharmaceutical Bulletin (Tokyo)
, vol.46
, pp. 22-33
-
-
Hongu, M.1
Tanaka, T.2
Funami, N.3
Saito, K.4
Arakawa, K.5
Matsumoto, M.6
Tsujihara, K.7
-
27
-
-
77953801665
-
Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: A randomized double-blind study
-
1:CAS:528:DC%2BC3cXns1CgsL8%3D
-
Hussey, E.K., R.L. Dobbins, R.R. Stoltz, N.L. Stockman, R.L. O'Connor-Semmes, A. Kapur, S.C. Murray, D. Layko, and D.J. Nunez. 2010. Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: A randomized double-blind study. Journal of Clinical Pharmacology 50: 636-646.
-
(2010)
Journal of Clinical Pharmacology
, vol.50
, pp. 636-646
-
-
Hussey, E.K.1
Dobbins, R.L.2
Stoltz, R.R.3
Stockman, N.L.4
O'Connor-Semmes, R.L.5
Kapur, A.6
Murray, S.C.7
Layko, D.8
Nunez, D.J.9
-
28
-
-
33845881411
-
Mechanisms linking obesity to insulin resistance and type 2 diabetes
-
1:CAS:528:DC%2BD28XhtlShtrzP
-
Kahn, S.E., R.L. Hull, and K.M. Ulzschneider. 2006. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444: 840-846.
-
(2006)
Nature
, vol.444
, pp. 840-846
-
-
Kahn, S.E.1
Hull, R.L.2
Ulzschneider, K.M.3
-
29
-
-
33845405222
-
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
-
Khan, S.E., S.M. Haffner, M.A. Heise, S.E. Kahn, S.M. Haffner, M.A. Heise, W.H. Herman, R.R. Holman, N.P. Jones, B.G. Kravitz, J.M. Lachin, M.C. O'Neill, B. Zinman, and G. Viberti. 2006. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. The New England Journal of Medicine 355: 2427-2443.
-
(2006)
The New England Journal of Medicine
, vol.355
, pp. 2427-2443
-
-
Khan, S.E.1
Haffner, S.M.2
Heise, M.A.3
Kahn, S.E.4
Haffner, S.M.5
Heise, M.A.6
Herman, W.H.7
Holman, R.R.8
Jones, N.P.9
Kravitz, B.G.10
Lachin, J.M.11
O'Neill, M.C.12
Zinman, B.13
Viberti, G.14
-
30
-
-
84892736281
-
Beneficial effect of betulinic acid on hyperglycemia via suppression of hepatic glucose production
-
1:CAS:528:DC%2BC3sXhvFOiurzP
-
Kim, S.J., H.Y. Quan, K.J. Kyong, D.Y. Kim, G.W. Kim, H.K. Jo, and S.H. Chung. 2014. Beneficial effect of betulinic acid on hyperglycemia via suppression of hepatic glucose production. Journal of Agricultural and Food Chemistry 62: 434-442.
-
(2014)
Journal of Agricultural and Food Chemistry
, vol.62
, pp. 434-442
-
-
Kim, S.J.1
Quan, H.Y.2
Kyong, K.J.3
Kim, D.Y.4
Kim, G.W.5
Jo, H.K.6
Chung, S.H.7
-
31
-
-
67349275999
-
Dapagliflozin: A novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus
-
1:CAS:528:DC%2BD1MXkslKqu7g%3D
-
Komoroski, B., N. Vachharajani, Y. Feng, L. Li, D. Kornhauser, and M. Pfister. 2009. Dapagliflozin: A novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clinical Pharmacology and Therapeutics 85: 513-519.
-
(2009)
Clinical Pharmacology and Therapeutics
, vol.85
, pp. 513-519
-
-
Komoroski, B.1
Vachharajani, N.2
Feng, Y.3
Li, L.4
Kornhauser, D.5
Pfister, M.6
-
32
-
-
84902240389
-
Luseogliflozin: First global approval
-
Markham, A., and S. Elkinson. 2014. Luseogliflozin: First global approval. Drugs 74: 945-950.
-
(2014)
Drugs
, vol.74
, pp. 945-950
-
-
Markham, A.1
Elkinson, S.2
-
33
-
-
64749099761
-
Glucose control by the kidney: An emerging target in diabetes
-
1:CAS:528:DC%2BD1MXlvFOjs7o%3D
-
Marsenic, O. 2009. Glucose control by the kidney: An emerging target in diabetes. American Journal of Kidney Disease 53: 875-883.
-
(2009)
American Journal of Kidney Disease
, vol.53
, pp. 875-883
-
-
Marsenic, O.1
-
34
-
-
0036737543
-
Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals
-
1:CAS:528:DC%2BD38XntVShsrk%3D
-
Matsuda, M., R.A. Defronzo, L. Glass, A. Consoil, M. Giordano, P. Bressler, and S. Delprato. 2002. Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. Metabolism 51: 1111-1119.
-
(2002)
Metabolism
, vol.51
, pp. 1111-1119
-
-
Matsuda, M.1
Defronzo, R.A.2
Glass, L.3
Consoil, A.4
Giordano, M.5
Bressler, P.6
Delprato, S.7
-
35
-
-
84893827104
-
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
-
1:CAS:528:DC%2BC2cXis1ersL0%3D 3904617
-
Merovci, A., C. Solis-Herrera, G. Daniele, R. Eldor, T.V. Fiorentino, D. Tripathy, J. Xiong, Z. Perez, L. Norton, M.A. Abdul-Ghani, and R.A. DeFronzo. 2014. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. The Journal of Clinical Investigation 124: 509-514.
-
(2014)
The Journal of Clinical Investigation
, vol.124
, pp. 509-514
-
-
Merovci, A.1
Solis-Herrera, C.2
Daniele, G.3
Eldor, R.4
Fiorentino, T.V.5
Tripathy, D.6
Xiong, J.7
Perez, Z.8
Norton, L.9
Abdul-Ghani, M.A.10
Defronzo, R.A.11
-
36
-
-
84872733237
-
Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects
-
1:CAS:528:DC%2BC3sXitlGisb4%3D
-
Miao, Z., G. Nucci, N. Amin, R. Sharma, V. Mascitti, M. Tugnait, A.D. Vaz, E. Callegari, and A.S. Kalgutkar. 2013. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metabolism and Disposition 41: 445-456.
-
(2013)
Drug Metabolism and Disposition
, vol.41
, pp. 445-456
-
-
Miao, Z.1
Nucci, G.2
Amin, N.3
Sharma, R.4
Mascitti, V.5
Tugnait, M.6
Vaz, A.D.7
Callegari, E.8
Kalgutkar, A.S.9
-
37
-
-
67349224047
-
Melatonin receptors in pancreatic islets: Good morning to a novel type 2 diabetes gene
-
1:CAS:528:DC%2BD1MXms1yhsrY%3D
-
Mulder, H., C. Nagorny, V. Lyssenko, and L. Groop. 2009. Melatonin receptors in pancreatic islets: Good morning to a novel type 2 diabetes gene. Diabetologia 52: 1240-1249.
-
(2009)
Diabetologia
, vol.52
, pp. 1240-1249
-
-
Mulder, H.1
Nagorny, C.2
Lyssenko, V.3
Groop, L.4
-
38
-
-
84874070590
-
Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats
-
Nagata, T., M. Fukazawa, K. Honda, T. Yata, M. Kawai, M. Yamane, N. Murao, K. Yamaguchi, M. Kato, T. Mitsui, Y. Suzuki, S. Ikeda, and Y. Kawabe. 2012. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. AJP: Endocrinology and Metabolism 304: E414-E423.
-
(2012)
AJP: Endocrinology and Metabolism
, vol.304
, pp. 414-E423
-
-
Nagata, T.1
Fukazawa, M.2
Honda, K.3
Yata, T.4
Kawai, M.5
Yamane, M.6
Murao, N.7
Yamaguchi, K.8
Kato, M.9
Mitsui, T.10
Suzuki, Y.11
Ikeda, S.12
Kawabe, Y.13
-
39
-
-
77949287535
-
Sodium-glucose co-transporter inhibitors: Progress and therapeutic potential in type 2 diabetes mellitus
-
1:CAS:528:DC%2BC3cXls1Sltbw%3D
-
Neumiller, J.J., J.R. White, and R.K. Campbell. 2010. Sodium-glucose co-transporter inhibitors: Progress and therapeutic potential in type 2 diabetes mellitus. Drugs 70: 377-385.
-
(2010)
Drugs
, vol.70
, pp. 377-385
-
-
Neumiller, J.J.1
White, J.R.2
Campbell, R.K.3
-
40
-
-
84866336965
-
Discovery of tofogliflozin, a novel c-arylglucoside with ano-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (sglt2) inhibitor for the treatment of type 2 diabetes
-
1:CAS:528:DC%2BC38XhtFOrurfN
-
Ohtake, Y., T. Sato, T. Kobayashi, M. Nishimoto, N. Taka, K. Takano, K. Yamamoto, M. Ohmori, M. Yamaguchi, K. Takami, S.Y. Yeu, K.H. Ahn, H. Matsuoka, K. Morikawa, M. Suzuki, H. Hagita, K. Ozawa, K. Yamaguchi, K. Kato, and S. Ikeda. 2012. Discovery of tofogliflozin, a novel c-arylglucoside with ano-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (sglt2) inhibitor for the treatment of type 2 diabetes. Journal of Medicinal Chemistry 55: 7828-7840.
-
(2012)
Journal of Medicinal Chemistry
, vol.55
, pp. 7828-7840
-
-
Ohtake, Y.1
Sato, T.2
Kobayashi, T.3
Nishimoto, M.4
Taka, N.5
Takano, K.6
Yamamoto, K.7
Ohmori, M.8
Yamaguchi, M.9
Takami, K.10
Yeu, S.Y.11
Ahn, K.H.12
Matsuoka, H.13
Morikawa, K.14
Suzuki, M.15
Hagita, H.16
Ozawa, K.17
Yamaguchi, K.18
Kato, K.19
Ikeda, S.20
more..
-
41
-
-
84900458799
-
Ipragliflozin: First global approval
-
1:CAS:528:DC%2BC2cXmsV2nsbw%3D
-
Poole, R.M., and R.T. Dungo. 2014. Ipragliflozin: First global approval. Drugs 74: 611-617.
-
(2014)
Drugs
, vol.74
, pp. 611-617
-
-
Poole, R.M.1
Dungo, R.T.2
-
42
-
-
33644688031
-
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
-
1:CAS:528:DC%2BD2MXht12gs7fK
-
Rahmoune, H., P.W. Thompson, J.M. Ward, C.D. Smith, G. Hong, and J. Brown. 2005. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54: 3427-3434.
-
(2005)
Diabetes
, vol.54
, pp. 3427-3434
-
-
Rahmoune, H.1
Thompson, P.W.2
Ward, J.M.3
Smith, C.D.4
Hong, G.5
Brown, J.6
-
43
-
-
0024160877
-
Role of insulin resistance in human disease
-
1:STN:280:DyaL1M%2Flt12msQ%3D%3D
-
Reaven, G.M. 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-1607.
-
(1988)
Diabetes
, vol.37
, pp. 1595-1607
-
-
Reaven, G.M.1
-
44
-
-
79956331954
-
Canagliflozin: A novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects
-
1:CAS:528:DC%2BC3MXoslaju7o%3D
-
Sha, S., D. Devineni, A. Ghosh, D. Polidori, S. Chien, D. Wexler, K. Shalayda, K. Demarest, and P. Rothenberg. 2011. Canagliflozin: A novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes, Obesity & Metabolism 13: 669-672.
-
(2011)
Diabetes, Obesity & Metabolism
, vol.13
, pp. 669-672
-
-
Sha, S.1
Devineni, D.2
Ghosh, A.3
Polidori, D.4
Chien, S.5
Wexler, D.6
Shalayda, K.7
Demarest, K.8
Rothenberg, P.9
-
45
-
-
84874291673
-
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
-
Stenlöf, K., W.T. Cefalu, K.A. Kim, M. Alba, K. Usiskin, C. Tong, W. Canovatchel, and G. Meininger. 2013. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes, Obesity & Metabolism 15: 372-382.
-
(2013)
Diabetes, Obesity & Metabolism
, vol.15
, pp. 372-382
-
-
Stenlöf, K.1
Cefalu, W.T.2
Kim, K.A.3
Alba, M.4
Usiskin, K.5
Tong, C.6
Canovatchel, W.7
Meininger, G.8
-
46
-
-
17044386953
-
Type 2 diabetes: Principles of pathogenesis and therapy
-
1:CAS:528:DC%2BD2MXjtF2iu7g%3D
-
Stumvoll, M., B.J. Goldstein, and T.W. van Haeften. 2005. Type 2 diabetes: Principles of pathogenesis and therapy. Lancet 365: 1333-1346.
-
(2005)
Lancet
, vol.365
, pp. 1333-1346
-
-
Stumvoll, M.1
Goldstein, B.J.2
Van Haeften, T.W.3
-
47
-
-
0030018911
-
Na(+)-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4-dehydroxyphlorizin derivatives based on a new concept
-
1:CAS:528:DyaK28XjvVKlurw%3D
-
Tsujihara, K., M. Hongu, K. Saito, M. Inamasu, K. Arakawa, A. Oku, and M. Matsumoto. 1996. Na(+)-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4-dehydroxyphlorizin derivatives based on a new concept. Chemical & Pharmaceutical Bulletin (Tokyo) 44: 1174-1180.
-
(1996)
Chemical & Pharmaceutical Bulletin (Tokyo)
, vol.44
, pp. 1174-1180
-
-
Tsujihara, K.1
Hongu, M.2
Saito, K.3
Inamasu, M.4
Arakawa, K.5
Oku, A.6
Matsumoto, M.7
-
48
-
-
1242317693
-
The SLC2 family of facilitated hexose and polyol transporters
-
1:CAS:528:DC%2BD2cXhtVygsLk%3D
-
Uldry, M., and B. Thorens. 2004. The SLC2 family of facilitated hexose and polyol transporters. Pflügers Archiv 447: 480-489.
-
(2004)
Pflügers Archiv
, vol.447
, pp. 480-489
-
-
Uldry, M.1
Thorens, B.2
-
49
-
-
69549095914
-
A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: Applicability of a novel insulin-independent treatment
-
1:CAS:528:DC%2BD1MXht1agtr3N 2732143
-
Wilding, J.P., P. Norwood, C. T'joen, A. Bastien, J.F. List, and F.T. Fiedorek. 2009. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: Applicability of a novel insulin-independent treatment. Diabetes Care 32: 1656-1662.
-
(2009)
Diabetes Care
, vol.32
, pp. 1656-1662
-
-
Wilding, J.P.1
Norwood, P.2
T'Joen, C.3
Bastien, A.4
List, J.F.5
Fiedorek, F.T.6
-
51
-
-
78651349221
-
Biology of human sodium glucose transporters
-
1:CAS:528:DC%2BC3MXns1Cms7g%3D
-
Wright, E.M., D.D. Loo, and B.A. Hirayama. 2011. Biology of human sodium glucose transporters. Physiological Reviews 91: 733-794.
-
(2011)
Physiological Reviews
, vol.91
, pp. 733-794
-
-
Wright, E.M.1
Loo, D.D.2
Hirayama, B.A.3
-
52
-
-
70549102064
-
Protective effects of fermented ginseng on streptozotocin-induced pancreatic β-cell damage through inhibition of NF-κB
-
19956901
-
Yuan, H.D., and S.H. Chung. 2010. Protective effects of fermented ginseng on streptozotocin-induced pancreatic β-cell damage through inhibition of NF-κB. International Journal of Molecular Medicine 25: 53-58.
-
(2010)
International Journal of Molecular Medicine
, vol.25
, pp. 53-58
-
-
Yuan, H.D.1
Chung, S.H.2
-
53
-
-
84864146681
-
LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial
-
1:CAS:528:DC%2BC38XhtVOmtrfP 3400893
-
Zambrowicz, B., J. Freiman, P.M. Brown, K.S. Frazier, A. Turnage, J. Bronner, D. Ruff, M. Shadoan, P. Banks, F. Mseeh, D.B. Rawlins, N.C. Goodwin, R. Mabon, B.A. Harrison, A. Wilson, A. Sands, and D.R. Powell. 2012. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clinical Pharmacology and Therapeutics 92: 158-169.
-
(2012)
Clinical Pharmacology and Therapeutics
, vol.92
, pp. 158-169
-
-
Zambrowicz, B.1
Freiman, J.2
Brown, P.M.3
Frazier, K.S.4
Turnage, A.5
Bronner, J.6
Ruff, D.7
Shadoan, M.8
Banks, P.9
Mseeh, F.10
Rawlins, D.B.11
Goodwin, N.C.12
Mabon, R.13
Harrison, B.A.14
Wilson, A.15
Sands, A.16
Powell, D.R.17
|